FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Otis William 		2. Issuer Name and Ticker or Trading Symbol

PURE BIOSCIENCE, INC. [ PURE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1725 GILLESPIE WAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/25/2017
(Street)

EL CAJON, CA 92020
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   9/25/2017     M    9066   A $0.60   181732   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   $0.75   9/25/2017     D   (1)       9066    8/1/2014   8/1/2019   Common Stock   9066     (1) 0   D    
Warrant   $0.60   9/25/2017     A   (1)    9066       8/1/2014   9/25/2017   Common Stock   9066     (1) 9066   D    
Warrant   $0.60   9/25/2017     M   (2)       9066    8/1/2014   9/25/2017   Common Stock   9066     (2) 0   D    

Explanation of Responses:
(1)  On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended.
(2)  In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised his 2014 Warrant in full and in cash on September 25, 2017.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Otis William
1725 GILLESPIE WAY
EL CAJON, CA 92020 		X



Signatures
/s/ William Otis 9/27/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more PURE Bioscience (PK) Charts.
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more PURE Bioscience (PK) Charts.